在低密度脂蛋白受体缺乏的小鼠中,甲福明并不能减轻 ангиотензин II 诱导的大动脉动脉瘤
bioRxiv : the preprint server for biology
|June 12, 2025
概括
在缺乏低密度脂蛋白受体的小鼠中,甲福明并没有防止血管新生素II诱导的大动脉动脉瘤形成. 这项研究表明,在这种特定的动脉样硬化和动脉瘤发育模式中,甲福明是无效的.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 代谢性疾病 代谢性疾病
背景情况:
- 甲福明是一种抗高血糖药物,此前已显示其在预防阿二酶诱导的大动脉动脉瘤的有效性,在apolipoprotein E缺乏的小鼠中.
- 与ApoE-/-小鼠相比,缺乏低密度脂蛋白受体 (LDLR-/-) 的小鼠为人类高胆固醇血症和明显的葡萄糖代谢提供了更相关的模型.
- 在LDLR-/-小鼠中,甲福明对血管素II诱导的大动脉动脉瘤形成的影响仍未得到研究.
研究的目的:
- 为了确定甲福明是否抑制LDLR-/-小鼠的血管新生素II诱导的大动脉动脉瘤形成.
- 为了评估甲福明在高胆固醇血症小鼠模型中的疗效,与人类条件相关.
主要方法:
- 雄性LDLR-/-小鼠接受了甲福林或载体治疗,并食西方饮食.
- ангиотензин II 输注了 4 周的时间来诱导大动脉动脉瘤.
- 测量了血甲福明水平,体重和大动脉尺寸.
主要成果:
- 梅特福林的使用导致体重减轻,证实了有效的药物输送.
- 血甲福明度通过质谱测量得到证实.
- 甲胺并没有显著减少上腹部或上升区域的大动脉直径.
结论:
- 在LDLR-/-小鼠中,甲福明未能减弱血管激素II诱导的大动脉动脉瘤形成.
- 这些发现表明,在这种特定的小鼠模型中,甲胺在预防动脉瘤发育方面并不有效.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492


